Haɗin gwiwar jama'a da masu zaman kansu, BioNTech, moderna, curevac, covid-19, coronavirus, allurar rigakafi:
20200320AD
BTM Innoations, Apeiron, SRI International, Iktos, magungunan rigakafi, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanfi,

A cikin Maris 16, Hukumar Turai ta ba da sanarwar cewa ta ba da Euro miliyan 80 don tallafawa kamfanin na CureVac na Jamus don hanzarta aiki a kan rigakafin cutar coronavirus. Wannan bayanin ya bayyana ne kwana guda bayan da majiyoyin gwamnatin ta Jamus suka ce gwamnatin Donald Trump na neman hanyar da za ta sami damar yin amfani da wannan rigakafin. Shin hakan yana nuna cewa akwai kamfani guda ɗaya kaɗai da ke aiki da mafita wanda yake da matukar mahimmanci ga bil'adama? WHO (Kungiyar Lafiya ta Duniya) ta wallafa bayanai kan irin waɗannan kamfanoni 13 a cikin gidajen yanar gizon ta, kuma ƙididdigar Global Data tana nuna cibiyoyi 30 waɗanda ke aiki akan wannan batun. Shin akwai damar da za mu iya magance matsalolinmu? Shaidan koyaushe yana cikin cikakken bayani.
A hukumance, kamfanoni daya ne kawai - Amurka Moderna - da ta wuce matakin gwaji na asibiti inda ake gwada maganin a cikin mutane. Ana yin gwaje-gwaje a Amurka a Cibiyar Nazarin Lafiya ta Washington a Seattle. Irin wannan saurin haɓakar rigakafin ƙwayar cuta ba a taɓa faruwa ba kuma yana yiwuwa saboda masana kimiyya zasu iya amfani da ƙwarewar tare da coronaviruses wanda ya haifar da annobar SARS da MERS. Duk da aikin rikodin rikodin, koda maganin yana tabbatar da lafiya da tasiri akan cutar, bazai yuwu ba aƙalla shekara guda.
Duk sauran 'yan wasan da ke son haɓakar rigakafin ƙwayar cuta ta coronavirus a halin yanzu suna kan matakan da suka dace na zamani. Matsakaicin matakin shine bincike a cikin dakunan gwaje-gwaje da dabbobin da kawai zasu iya haifar da yin rigakafi a cikin kusan shekara guda da rabi. Yana da wuya a faɗi wa ke cin nasarar tseren, amma babban damar ba farawa ba ne, amma manyan kamfanonin harhada magunguna.

Kamfanin Jamus na CureVac ya yi aiki tare da wata cibiyar jama'a da ke Oslo, abin da ake kira Hadin gwiwar Tsarin Bala'i (CEPI). Suna aiki da wani allurar rigakafin mRNA. Kamar ƙwararren ɗan Amurka mai suna Moderna mRNA, CureVac yana so ya tabbatar da cewa za a haɓaka da ƙananan ƙwayoyin rigakafin mRNA da sauri fiye da alluran gargajiya, kuma suna da niyyar zuwa gwajin asibiti na farkon wannan bazara.
Kamar CureVac - kamfanin Jamus na BioNTech, wanda ke haɓaka allurar rigakafin mRNA don cutar kansa da mura - shine batun yiwuwar haɗin gwiwa tare da mashahurin magunguna Pfizer don haɓaka rigakafin cutar Covid19. Sanofi da Janssen suna aiki tare da Ma'aikatar Binciken Bayanai ta Amurka (US Biomedical Advanced Office for Research and Development) (BARDA) kuma suna kan matakan da suka dace.
Hakanan ana cigaba da ayyuka da yawa. A ranar Litinin2 EUR miliyan 7 na tallafin da ke ƙarƙashin shirin Horizon2020 an kasafta ga ƙungiyar 'yan Danish-kamfanoni masu zaman kansu: kamfanonin ilmin kimiya na kimiyyar ilimin kimiyya na ExpreS2ion da AdaptVac. Conungiyar ta yi niyyar ƙaddamar da gwaji na I / IIa na asibiti don maganin a cikin watanni 12.

Yayinda rigakafin na farko na iya kasancewa a cikin tsararren lokaci har zuwa bazara, mai yiwuwa masu tsara zasu buƙaci shekara ɗaya zuwa biyu na gwajin ɗan adam don tabbatar da cewa maganin yana cikin lafiya da tasiri. Bayan samun amincewa, kamfanoni na iya fara samarwa da rarraba allurar a kan sikelin kasuwanci, wanda kuma ya dauki lokaci mai tsawo. A takaice, duniya ta ga allurar riga-kafi ta Covid-19 kawai a kusa da tsakiyar 2121.
Koyaya, ya nuna cewa maganin ba shine kawai ceto ba. Yawancin kamfanoni suna tsammanin haɓaka sabbin magungunan rigakafi ko daidaita da magungunan gwaji na yanzu don yaƙar sabuwar ƙwayar. Wannan aiki ne mai wahala domin, ba kamar ƙwayoyin cuta ba, ƙwayoyin cuta suna ɓoye cikin sel namu. Wannan yana nufin cewa magunguna waɗanda ke dakatar da kwayar cutar mafi yawan lokuta suna shafar ƙwayoyinmu, wanda zai haifar da sakamako masu illa.
Kamfanin Iktos na Parisi na Iktos da ke hulɗar da magunguna ta hanyar fasahar mutum ya fara haɗin gwiwa tare da kamfanin guba na Amurka SRI International. Manufar haɗin gwiwar ita ce haɓaka sababbin magungunan rigakafi don lura da Covid19 da sauran nau'ikan ƙwayoyin cuta. Kamfanin kere-kere na Austrian Apeiron ya fara gwajin asibiti na gwaji na II na wani ɗan takara game da Covid-19 a ƙarshen Fabrairu. Magungunan furotin sun riga sun kammala karatun Phase I da II a cikin lura da mummunan raunin huhu kuma ana tsammanin yin aiki ta hanyar kwaikwayon furotin wanda coronavirus ke ɗauka yayin mamaye huhu. Hakanan akwai wasu ayyukan da yawa don nufin canza amfani da magungunan rigakafin da aka yarda da su a cikin maganin Covid-19. Wannan yana da fa'ida cewa an riga an san lafiyar miyagun ƙwayoyi kuma zai iya isa kasuwa da sauri. Masu bincike daga Göttingen da Berlin, Jamus, yanzu suna binciken yiwuwar kamostat mesylate - magani ne da aka amince da shi a Japan don magance cututtukan cututtukan cututtukan fata.

http: //www.e-manus.pl/